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Abstract
Background: Primary hyperparathyroidism is characterized by enlarged parathyroid glands due to an adenoma
(80–85 %) or multiglandular disease (~15 %) causing hypersecretion of parathyroid hormone (PTH) and generally
hypercalcemia. Parathyroid cancer is rare (<1–5 %). The epigenetic mark 5-hydroxymethylcytosine (5hmC) is
reduced in various cancers, and this may involve reduced expression of the ten-eleven translocation 1 (TET1)
enzyme. Here, we have performed novel experiments to determine the 5hmC level and TET1 protein expression in
43 parathyroid adenomas (PAs) and 17 parathyroid carcinomas (PCs) from patients who had local invasion or
metastases and to address a potential growth regulatory role of TET1.
Results: The global 5hmC level was determined by a semi-quantitative DNA immune-dot blot assay in a smaller
number of tumors. The global 5hmC level was reduced in nine PCs and 15 PAs compared to four normal tissue
samples (p < 0.05), and it was most severely reduced in the PCs. By immunohistochemistry, all 17 PCs stained
negatively for 5hmC and TET1 showed negative or variably heterogeneous staining for the majority. All 43 PAs
displayed positive 5hmC staining, and a similar aberrant staining pattern of 5hmC and TET1 was seen in about half
of the PAs. Western blotting analysis of two PCs and nine PAs showed variable TET1 protein expression levels.
A significantly higher tumor weight was associated to PAs displaying a more severe aberrant staining pattern of
5hmC and TET1. Overexpression of TET1 in a colony forming assay inhibited parathyroid tumor cell growth.
Conclusions: 5hmC can discriminate between PAs and PCs. Whether 5hmC represents a novel marker for
malignancy warrants further analysis in additional parathyroid tumor cohorts. The results support a growth
regulatory role of TET1 in parathyroid tissue.
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Background
Primary hyperparathyroidism (pHPT) is a common
endocrine disease characterized by excessive secretion of
PTH and increased level of serum calcium. Eighty to
85 % of pHPT cases are due to a benign, single adenoma
and 15 % to multiglandular disease. Parathyroid carcin-
oma (PC) is rare, and depending on whether it is diag-
nosed based on pathological examination alone or
biological evidence of malignant behavior, it accounts
for less than 1 to <5 % of cases of pHPT [1–9]. An ana-
lysis of 286 PC cases from the USA revealed a 5-year
survival rate of 86 % and a 10-year survival rate of 49 %
[10]. WHO criteria for PC include demonstration of an in-
vasive growth pattern or distant metastasis. Pathological
diagnosis of PC is a challenge also because there is no
widely available and completely sensitive or specific im-
munohistochemical marker available. Somatic inactivating
mutations of CDC73/HRPT2, encoding parafibromin,
are common in PCs defined by malignant behavior
(approximately 70 %) and rare (<1 %) in benign disease.
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has been suggested a marker for PC by some investigators
but has been reported to be less useful by others [7, 11–14].
In PC patients who had local invasion and/or metastases
at initial surgery or follow-up, negative staining for
parafibromin was found in 64 % and in 10 % of patients
whose diagnosis was based only on classic histological
features [15].
The epigenetic mark 5-hydroxymethylcytosine (5hmC)
was rediscovered in mammalian cells and shown to
be an intermediate in DNA demethylation of 5-
methylcytosine. The ten-eleven translocation (TET)
family of proteins (TET1, TET2, TET3) catalyze conver-
sion of 5-methylcytosine to 5hmC, 5-formylcytosine, and
5-carboxylcytosine and renders passive or active DNA de-
methylation [16, 17]. Growing evidence suggests that
5hmC not only is an intermediate in DNA demethylation
but also acts as an epigenetic mark that regulates gene ex-
pression by recruiting DNA-binding proteins [18]. 5hmC
is present in many tissues and cell types and is frequently
deregulated in cancer, by decreased levels of 5hmC when
compared to normal tissues and some but not all tumors
show changes in TET expression levels [19–28].
Here, we have for the first time determined levels of
5hmC and TET1 in PAs and PCs and investigated
whether TET1 could play a role in parathyroid tumor
cell growth regulation. Our study show that negative
staining for 5hmC is a frequent event in PCs compared
to PAs and suggest a novel potential marker for parathy-
roid malignancy. Furthermore, our data suggest that
TET1 has a growth regulatory role in parathyroid tissue.
Methods
Tissue specimens
Parathyroid carcinomas (n = 17) from 15 patients who
had local invasion and/or metastases and single parathy-
roid adenomas (n = 43) were acquired from patients
diagnosed and operated on in clinical routine at the
Uppsala University Hospital, Uppsala, Sweden, Department
of Surgery, Royal North Shore Hospital, St Leonards,
Australia, and Hammersmith Hospital, London, UK.
Apparent normal parathyroid tissue (n = 4) was obtained
as normal parathyroid gland biopsies inadvertently re-
moved in patients subjected to parathyroidectomy. These
specimens (“normals”) that stained positive for para-
thyroid hormone (PTH), by immunohistochemistry of
frozen tissue sections, were used for comparisons with
parathyroid tumor tissues. Clinical data for patients with
parathyroid adenoma or carcinoma are shown in
Additional file 1: Table S1 and Additional file 2: Table S2,
respectively. Informed consent and approval of the
Uppsala Local Ethical Committee, the Northern Sydney
Local Health District Human Research Ethics Committee,
and by the Imperial College Research Ethics Committee,
London, were achieved.
DNA sampling and dot blot analysis
Genomic DNA was extracted from frozen surgical speci-
mens or cultured cells using DNeasy Blood and tissue
kit (Qiagen GmbH, Hilden, Germany) and paraffin-
embedded tissue sections using QIAamp DNA FFPE
tissue kit (Qiagen GmbH) according to manufacturer’s
instructions. 5hmC DNA standard (Zymo Research
Corporation, Irvine, CA, USA) was used as a control.
One microgram DNA was denatured in 0.1 M NaOH at
95 °C for 10 min, then placed on ice and neutralized
with 1 M ammonium acetate. Twofold serial dilutions of
the DNA samples were prepared and spotted onto
Hybond-N+ nylon membrane (GE Healthcare, Piscataway,
NJ, USA) in a Bio-Dot apparatus (Bio-Rad Laboratories,
Inc., Hercules, CA, USA). The spotted membrane was
fixed with UV irradiation (GS Gene Linker UV chamber,
Bio-Rad), blocked with 5 % skimmed milk, and incubated
overnight with a rabbit polyclonal anti-5hmC antibody
[19, 25, 29] (1:10K dilution, 39791; Active Motif, Carlsbad,
CA, USA) and then appropriate HRP-conjugated sec-
ondary antibody. Signals were visualized with the en-
hanced chemiluminescence system (GE Healthcare).
The same membrane was stained with 0.02 % methy-
lene blue in 0.3 M sodium acetate to ensure equal spot-
ting of the total DNA on the membrane. The second
dot blot signal from the top for each serial dilution was
used to quantify intensities by the NIH Image-J soft-
ware according to the program’s instructions [30] and
the 5hmC relative intensity was calculated by dividing
the value for each sample by the value of the standard.
A linear relationship was obtained for the serially
diluted 5hmC standard (not shown).
Immunostaining
Immunohistochemistry: Paraffin embedded tissue sections
were deparaffinized with xylene and rehydrated through
descending alcohol concentrations and distilled water.
Sections were treated with 3 % hydrogen peroxide and
heated in EDTA pH 8.0 (Life Technologies Corporation,
Carlsbad, CA, USA ), for 40 min with microwave at
300-W power. The sections then were incubated with
2 M HCl for 2.5 min and treated with normal goat serum
and the rabbit polyclonal anti-5hmC antibody (1:6000
dilution, Active Motif), rabbit polyclonal anti-TET1
(HPA019032; Prestige Antibodies, Sigma-Aldrich Sweden
AB, Stockholm, Sweden) or normal horse serum and goat
polyclonal anti-PTH antibody (sc-9678; Santa Cruz
Biotechnology, Santa Cruz, CA, USA). The sections were
washed three times with PBS, then incubated with a
proper secondary antibody and ABC complex. DAB was
used for visualization. Frozen tissue sections (apparent
normal parathyroid tissue and parathyroid carcinoma #12
and #13) were first fixed in formalin and then stained as
described above but excluding incubation in 2 M HCl.
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Immunofluorescence: The sections were treated and incu-
bated with rabbit polyclonal anti-5hmC antibody (1:6000
dilution, Active Motif) as mentioned above, then washed
three times with PBS (0.05 % Tween20) and incubated
with proper fluorescence secondary antibody (Alexa 594,
Life Technologies). Sections were washed again and
mounted with Vectashield with Dapi (Vector Laboratories,
Inc., Burlingame, CA, USA). Normal liver tissue was used
as positive control for TET1.
Western blotting
Protein extracts prepared using Cytobuster Protein Extract
Reagent (Merck Millipore, Billerica, MA, USA) with
complete protease inhibitor cocktail (Roche Diagnostics
Scandinavia AB, Bromma, Sweden). Rabbit polyclonal
anti-TET1 (GTX124207; GeneTex Inc, Irvine, CA, USA)
and goat polyclonal anti-Actin (sc-1616; Santa Cruz
Biotechnology) were used. After incubation with the ap-
propriate secondary antibody, bands were visualized using
the enhanced chemiluminescence system (GE Healthcare).
Colony formation assay and measurement of apoptosis
sHPT-1 parathyroid tumor cells [31] were distributed
onto 35-mm dishes (2 × 105) in DMEM/10 % fetal bo-
vine serum (Sigma) and transfected in triplicates with
1 μg pIRES-hrGFP ll-TET1-FL [32] or empty vector
(pIRES-hrGFP ll) using FuGENE 6 transfection reagent
(Promega Biotech AB, Nacka, Sweden), according to
manufacturer’s instructions. Twenty four hours after
transfection, 2000 sHPT-1 cells were distributed onto
six-well plates in triplicates. After additional 24 h, a fresh
medium with 0.2 mg/ml Neomycin (G418, Sigma-
Aldrich) was added and refreshed every 72 h. After
10-day selection in Neomycin, the cells were fixed with
10 % acetic acid/10 % methanol and stained with 0.4 %
crystal violet, and visible colonies were counted. HEK293T
cells (1.5 × 106) were transfected with FuGENE 6 transfec-
tion reagent (Promega Biotech AB). After 24 h, 8000
HEK293T cells were distributed onto six-well plates in
triplicates and the next day 0.2 mg/ml Neomycin was
added to culture medium. After 10 days in selection cells
were fixed, stained and counted as described above. Suc-
cessful transfection was determined by real-time quantita-
tive RT-PCR and western blotting for sHPT-1 and
HEK293T, after 72 h. The human parathyroid tumor cell
line sHPT-1 was used at cell passages 18–30, and the cells
were routinely tested for PTH expression by immuno-
staining of cultured fixed cells [31]. The human embryonic
kidney cell line HEK293T was obtained from ATCC
(LGC, Promochem, Sweden) and used at cell passages
10–30. Apoptosis was measured in sHPT-1 cells 72 h
after transfection and after 10 days of antibiotic
selection, using the Cell Death Detection ELISA kit
(Roche Molecular Biochemicals, Mannheim, Germany),
according to the manufacturer’s instructions. As a posi-
tive control, cells were incubated with 0.1 μg/ml camp-
tothecin (Sigma-Aldrich) for 72 h. Transfected cells
were also incubated with FITC-labeled annexin V and
propidium iodide (Sigma-Aldrich) and analyzed by flow
cytometry on a FACS Canto ІІ (BD Biosciences).
Annexin V-FITC binds to phosphatidylserine translocated
to the external portion of the membrane as a marker of
apoptosis, and propidium iodide distinguishes dead cells
with ruptured membrane.
Real-time quantitative PCR
DNA-free total RNA was extracted using RNeasy Plus
Mini kit (Qiagen GmbH) according to manufacturer’s
instructions and successful treatment with DNase I of all
RNA preparations using TURBO DNA-free™ kit (Life
Technologies Corporation) was established by PCR ana-
lysis. After reverse transcription of RNA preparations
with random hexamer primers using First-strand comple-
mentary DNA (cDNA) synthesis kit (GE Healthcare), real-
time quantitative RT-PCR was performed on StepOnePlus
RealTime PCR systems (Life Technologies Corporation)
using TaqMan gene expression Master Mix and assays
for TET1 transcript (Hs00286756_m1) and GAPDH
(Hs02758991_g1). Each cDNA sample was analyzed in
triplicate.
Statistical analysis
ANOVA test was used to calculate differences in relative
5hmC level between the three biological groups and to
compare clinical data between the four groups of aden-
omas. Bonferroni test was used to adjust the p values
(due to having a few number of samples, Kruskal-Wallis
test was used to check the significance of the p values
obtained from the ANOVA test). Differences in colony
formation assay and real-time quantitative RT-PCR was
evaluated using unpaired t test, and data are presented
as mean ± SEM. Statistical analysis was performed using
R version 3.1.1 (2014-07-10). p < 0.05 was considered
significant.
Results
Reduced global level of 5-hydroxymethylcytosine in
parathyroid tumors
A DNA immune-dot blot assay was established using a
previously validated rabbit polyclonal anti-5hmC antibody
[19, 25, 29]. Comparisons of twofold serial dilutions of
total DNA isolated from PCs (n = 9), PAs (n = 15), and
apparent normal parathyroid biopsies (n = 4) revealed a
significantly (p < 0.05) reduced level of 5hmC in the aden-
omas and the carcinomas compared to the normal tissue
samples (Fig. 1a, b). The global 5hmC level was most
severely reduced in the PCs.
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Fig. 1 DNA immune-dot blot assay of 5hmC using a rabbit polyclonal anti-5hmC antibody. a Analysis of twofold serial dilutions of DNA. Standard
(control 5hmC-DNA), normal parathyroid tissue specimens (n = 4), PAs (n = 15), and PCs (n = 9). MB methylene blue loading control represents the
least diluted DNA sample. b Quantification of the results in a. *p < 0.05
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Immunohistochemistry of 5hmC discriminates between
adenoma and carcinoma
Additional PCs were available for immunohistochemical
analysis. In comparison to normal parathyroid cells that
stained positively, all 17 analyzed carcinomas from 15 pa-
tients stained negatively for 5hmC (Fig. 2 and Additional
file 3: Table S3, denoted, − negative, undetectable). These
results are in line with those obtained from the DNA
immune-dot blot assay, where the global 5hmC level was
very low to almost undetectable in the analyzed PCs
(Fig. 1a, b).
In contrast, the observed staining patterns of the
adenomas were generally heterogeneous with different
appearances and these were denoted with M (mosaic, a
mixture of positive and negative cells); VH (variable
heterogeneous, areas with positive staining together with
areas of negative staining, and + (almost all cells stained
positive regardless of strength). The results are summa-
rized in Additional file 3: Table S4-S7 and representative
staining patterns are shown in Fig. 3a, b. Overall, 7
adenomas showed positive staining for almost all cells
(+, Additional file 3: Table S4) and 36 PAs stained posi-
tively for 5hmC but with the aberrant variable appear-
ance described above. Of the 36 PAs with aberrant
variable appearance of 5hmC, 23 adenomas showed mo-
saic staining (M) with a mixture of positive and negative
cells (Additional file 3: Table S4–S6), 6 adenomas
showed mosaic staining (M) together with variable het-
erogeneity (VH), areas of positive staining together with
areas of negative staining (Additional file 3: Table S6),
and 7 adenomas showed VH only (Additional file 3:
Table S7). The presence of 5hmC negatively staining
cells in PAs is consistent with the observed reduction of
the global 5hmC level by the DNA immune-dot blot
assay (Fig. 1a, b). Also, three PAs (#22, 24, 29) that
stained positive for almost all cells regardless of strength
(+, Additional file 3: Table S4) showed reduced global
5hmC level (Fig. 1a).
Fig. 2 Immunohistochemical analysis of a normal parathyroid tissue specimen (frozen) and paraffin imbedded PCs (n = 2). Top left, staining without
primary antibody. Same numbering of the PCs as in Additional file 3: Table S3. Both carcinomas stained negative for 5hmC, carcinoma 2 positive for
TET1, and carcinoma 8 negative for TET1. Scale bars, 50 μm (normal parathyroid) and 100 μm (PCs). Staining results of additional PCs are shown in
Additional file 4: Figure S1
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Fig. 3 (See legend on next page.)
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To summarize, all 17 PCs showed negative/undetectable
staining for 5hmC and all 43 PAs contained 5hmC
positive cells. 5hmC may therefore be used as a marker to
discriminate between benign and malignant parathyroid
tumors.
TET1 expression and 5hmC level establish groups of PAs
and relate to tumor weight
TET protein family members are responsible for the
conversion of 5mC to 5hmC (16) and altered 5hmC
levels may be caused by deregulated TET expression
[26–28]. We therefore performed immunohistochemical
analysis of TET1 in our cohort of PAs and PCs
(Additional file 3: Table S3–S7, Figs. 2 and 3a). The
observed staining patterns of TET1 resembled those of
5hmC. TET1 expression was undetectable in 7 out of
the 17 PCs (Additional file 3: Table S3), variable hetero-
geneous (VH), with areas of positive staining together
with areas of negative staining, was seen in 6 carcin-
omas, and 4 carcinomas showed positive staining in
most cells, regardless of strength (+). A primary PC and
metastasis from the same patient were available for ana-
lysis and showed the same staining patterns of 5hmC
and TET1 (Additional file 3: Table S3, tumor nos. 14
and 15). The staining for TET1 in the PCs and PAs was
nuclear or nuclear/cytoplasmic, with no associations to
overall staining patterns (+, M, VH, data not shown).
Staining for parafibromin, encoded by HRPT2, was
available for PC nos. 1–9. No associations of negative or
positive parafibromin staining to TET1 expression (−, +,
VH) were observed (Additional file 2: Table S2 and
Additional file 3: Table S3). The staining results for
5hmC and TET1 were used to group the analyzed PAs
as presented in Additional file 3: Tables S4–S7.
Additional file 3: Table S4 presents tumors with analo-
gous mosaic staining (M) of both 5hmC and TET1 and
tumors with positive staining of 5hmC/TET1 for almost
all cells regardless of strength (+). Additional file 3:
Table S5 contains PAs with mosaic (M) appearance of
5hmC and positive staining of TET1 for almost all cells
regardless of strength (+). Additional file 3: Tables S6
and S7 present adenomas with more severe aberrant
staining patterns. Mosaic (M) staining for 5hmC to-
gether with VH (variable heterogeneous, with areas of
positive staining together with areas of negative staining,
Additional file 3: Table S6) or analogous VH appearance
(See figure on previous page.)
Fig. 3 a Representative results from immunohistochemical analysis of 5hmC and TET1 in PAs (n = 4). Ad19 shows mosaic staining (M) for both
(a mixture of positive and negative cells), Ad24 shows + (almost all cells stained positive regardless of strength), Ad40 shows M for 5hmC and + for
TET1, and Ad55 shows VH (variable heterogeneous, areas with positive staining together with areas of negative staining). Scale bars, 50 μm (Ad 19,
Ad24, Ad40) and 100 μm (Ad55). b Immunofluorescence was applied to demonstrate typical appearance of mosaic staining (M) of 5hmC at two
magnifications: a scale bar 100 μm; b scale bar 50 μm
Fig. 4 Western blotting analysis of TET1. a Transfected TET1 (sHPT-1
cells), PA51, PC11, and PC 10. b PAs (n = 9)
Fig. 5 Association of PAs of Additional file 3: Table S6 and S7 to tumor
weight (and not to serum PTH, serum calcium or age). These PAs
showed a more severe aberrant staining pattern of 5hmC and TET1
(M, VH). Clinical data is presented in Additional file 1: Table S1
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Fig. 6 (See legend on next page.)
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for 5hmC and TET1 (Additional file 3: Table S7). All
PAs showed positive TET1 staining but with a similar
aberrant staining pattern (M, VH) of TET1 and 5hmC in
about half of the PAs. PTH expression was evident also
in areas of negative 5hmC and TET1 staining (data not
shown). Western blotting analysis was also done for
TET1 and showed very low expression levels in the two
analyzed PCs (Fig. 4a) and low to variable expression
levels in the nine analyzed adenomas (Fig. 4b). When
clinical parameters (Additional file 1: Table S1) of the
patients (serum PTH, serum calcium, tumor weight,
age) were related to the staining results of the different
PA groups (Additional file 3: Table S4-S7), PAs of
Additional file 3: Table S6 and S7 was found to be asso-
ciated with a higher tumor weight (Fig. 5). Thus, a more
severe aberrant staining pattern of 5hmC and TET1 as-
sociated to tumor mass and may therefore interfere with
the tumor cell growth regulatory control.
A growth regulatory role of TET1 in parathyroid cells
In order to test experimentally whether TET1 could
interfere with parathyroid cellular growth, the parathy-
roid tumor cell line sHPT-1 and also HEK293T cells
were transfected with a TET1 expression vector or
empty vector in a colony formation assay. Increased ex-
pression of TET1 and increased level of 5hmC were
detected after transfection (Fig. 6a, b), and this resulted
in a significant reduced number and also size of sHPT-1
cell colonies (Fig. 6c, d). This was caused by reduced
growth capability as no effect on apoptosis was detected
after transfection of TET1 to sHPT-1 cells, as deter-
mined by quantifying cytoplasmic histone-associated-
DNA-fragments and by flow cytometry of cells stained
with annexin V-FITC and propidium iodide (Fig. 6e, f ).
No growth inhibitory effect was seen in HEK293T
cells (Fig. 6c, d). Overall, these results strongly sup-
port a growth regulatory role of TET1 in parathyroid
tumor cells.
Discussion
PC is difficult to diagnose; it has been reported that up
to half of metastatic or recurrent PCs were first diag-
nosed as benign [33]. Correct diagnosis may suggest
aggressive surgery to decrease the risk of recurrence.
Several immunohistochemical markers of parathyroid
malignancy have been suggested (e.g., APC, galectin-3,
parafibromin, PGP9.5, Rb), but none has been widely
accepted as highly sensitive and specific [7, 9]. Our novel
results demonstrated that all 17 analyzed PCs stained
negatively for 5hmC. In contrast, all 43 adenomas
showed positive staining for 5hmC. Thus, it seems that
5hmC can discriminate between PAs and PCs. We sug-
gest that negative staining for 5hmC may present a novel
potential marker for parathyroid malignancy and that
this warrants investigations in additional cohorts of
parathyroid tumors from patients with pHPT.
TET1 was first identified as a fusion partner of the
mixed lineage leukemia (MLL) gene in acute myeloid
leukemia, and it is now clear that TET1 plays an essential
oncogenic role in MLL-rearranged leukemia [27, 28, 34].
On the contrary, in many solid tumors, including breast,
lung, prostate, and colorectal, TET1 expression is down-
regulated with reduced levels of 5hmC, and TET1 muta-
tions are rarely observed [22, 26–28]. TET1 has been
shown to play a role as tumor suppressor in breast, pros-
tate, and colon cancers [35–37].
We found that expression of TET1 was undetectable
in 7 out of the 17 PCs (41 %) and in 6 PCs the expres-
sion of TET1 was heterogeneous with areas of positive
cells together with areas of negative cells. Since a clear
correlation between decreased 5hmC levels and TET1
expression was observed only in 41 % of the PCs, other
mechanisms must be involved. Besides indirect mecha-
nisms, it is possible that TET2 also contributes to the
observed reduced levels of 5hmC in some of the ana-
lyzed tumors [26, 28]. This will be addressed in future
experiments when an appropriate antibody to TET2 is
available.
A significantly higher tumor weight was found associ-
ated to PAs that displayed a more severe aberrant stain-
ing pattern of 5hmC and TET1. This strongly suggests
a growth regulatory role of 5hmC and TET1. Consist-
ently, overexpression of TET1 resulted in inhibition of
parathyroid tumor cell growth. These observations sup-
port a possible role of TET1 as a tumor suppressor
gene in this tissue.
(See figure on previous page.)
Fig. 6 Colony formation assay in the parathyroid cell line sHPT-1 and HEK293T cells. a Transfection of a TET1 expression vector and not the empty
vector resulted in increased expression of TET1 at the messenger RNA (mRNA) and protein levels and b increased the global level of 5hmC (lanes 1
and 3, transfection of sHPT-1 cells for 72 h and 10 days, respectively; lanes 2 and 4, empty vector). c Colony formation assay, representative results are
shown. Transfected cells were selected by incubation with G418 (neomycin) for 10 days. sHPT-1 cells also appeared as smaller colonies not necessarily
apparent in c. d Quantification of triplicates (mean ± SEM); sHPT-1/TET1 = 46 ± 7.1 and sHPT-1/empty vector = 175 ± 14.9. HEK293T/TET1 = 176 ± 5.6 and
HEK293T/empty vector = 190.6 ± 13.7. e Effects on apoptosis was analyzed in triplicates by quantifying cytoplasmic histone-associated-DNA-fragments
72 h after transfection and after 10 days of G418 selection. Incubation in 0.1 μg/ml camptothecin for 72 h was used as a positive control. f Flow
cytometry analysis of sHPT-1 cells 72 h after transfection and after staining with annexin V-FITC and propidium iodide. Early apoptotic cell population
in the upper left quadrant and late apoptotic cells in the upper right quadrant. Alive and dead cell populations in the lower left and right quadrant,
respectively. Incubation in 0.1 μg/ml camptothecin for 4 h was used as a positive control (data not shown)
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Reduced expression of TET1 is expected to result in
direct deregulation of parathyroid target genes, as for ex-
ample described in colon cancer for the DKK3 and
DKK4 inhibitors of the WNT pathway [37]. Interest-
ingly, impaired expression of another inhibitor of the
WNT signaling pathway by DNA methylation, the tumor
suppressor protein APC (adenomatous polyposis coli),
has been associated with PC malignancy [38, 39].
Conclusions
PC is very rare, and in the absence of disseminated
disease, it is sometimes difficult to distinguish PC from
benign adenoma. At present, a widely available and sen-
sitive or specific immunohistochemical marker for PC is
not available. Here, we have analyzed a relatively large
number of PCs and found 5hmC to present a new po-
tential negative marker for parathyroid malignancy. Our
novel findings also include an association of a more ab-
errant immunohistochemical staining pattern of 5hmC
and TET1 to tumor weight for the PAs and a direct
demonstration in vitro of a growth regulatory role for
TET1 in parathyroid tumor cells.
Additional files
Additional file 1: Table S1. Clinical data (serum PTH, serum calcium,
tumor weight, age) for patients with parathyroid adenoma. (EPS 3563 kb)
Additional file 2: Table S2. Clinical data for patients with parathyroid
carcinoma. Tumor nos. 1–9, 13, 14, 16, and 17 present primary PCs and
10–12 and 15 metastases. Tumor nos. 10 and 11 and 14 and 15 were
from the same patient, respectively. The following five PCs have been
published previously. Tumor no. 3 [13], no. 4 [40], and no. 11–13 [41].
Negative staining for parafibromin was detected in PC nos. 2, 3, and 5–8
and positive staining in nos. 1, 4, and 9 (unpublished results). (EPS 1549 kb)
Additional file 3: Tables S3–S7. Table S3. IHC results for carcinomas.
Table S4–S7. IHC results for adenomas. (EPS 3060 kb)
Additional file 4: Figure S1. A, Immunohistochemical analysis of 5hmC
and TET1 in paraffin imbedded PCs. Scale bar, 100 μm. All PCs stained
positive for PTH (not shown). Same numbering of the PCs as in
Additional file 3: Table S3. Carcinoma nos. 2 and 8 are shown in Fig. 2. B,
Normal liver tissue was used as positive control and stained with or
without the primary TET1 antibody. Clear TET1 nuclear staining was
observed only in the presence of the primary antibody. Scale bar,
100 μm. (EPS 324013 kb)
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